| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于近日收到公司首 次公开发行股票并在创业板上市以及向不特定对象发行可转换公司债券项目的 保荐机构东兴证券股份有限公司（以下简称"东兴证券"）出具的《关于更换持 续督导保荐代表人的通知函》，获悉东兴证券原委派的保荐代表人周磊先生因工 作变动离职，不再继续担任公司持续督导保荐代表人。为保证公司持续督导工作 的有序进行，东兴证券委派吴时迪先生（简历见附件）接替周磊先生担任公司持 续督导保荐代表人，继续履行持续督导职责。 本次保荐代表人更换后，负责公司持续督导工作的保荐代表人为林苏钦女士 和吴时迪先生，持续督导期限直至持续督导义务结束为止。 深圳市易瑞生物技术股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司 董事会 2025 年 10 月 15 日 1 附件 ...

Core Viewpoint - The company, EasyReel Bio, is undergoing significant changes due to frequent shareholder reductions and a strategic shift away from its in vitro diagnostic business, which has seen a drastic decline in demand, particularly for respiratory infectious disease testing products [2][7]. Shareholder Reduction - EasyReel Bio's controlling shareholder, EasyReel (Hainan) Venture Capital Co., Ltd., plans to reduce its holdings by up to 11,521,758 shares, representing 2.84% of the total share capital [3] - Other shareholders, EasyDarui and EasyKairui, also plan to reduce their holdings by 288,500 shares (0.07%) and 341,800 shares (0.08%), respectively [3] - If the maximum reduction occurs, the total cash outflow for the shareholders could reach approximately 1.23 million yuan based on the closing price of 10.12 yuan per share on October 13 [3] Business Performance and Strategy Shift - EasyReel Bio's revenue has significantly declined in 2023, with total revenue of 253 million yuan, a year-on-year decrease of 63.01%, and a net loss of 185 million yuan [7] - The in vitro diagnostic business, which once contributed up to 70% of revenue, has seen a drastic reduction in income, dropping to 47.7 million yuan in 2023, a 90.45% decline [7][8] - The company has shifted its focus back to food safety rapid testing and animal diagnostics, with food safety revenue showing a slight increase of 5.29% in 2024 [8] Historical Financial Performance - From 2020 to 2022, EasyReel Bio's revenue grew significantly due to the COVID-19 pandemic, with total revenues of 259 million yuan, 598 million yuan, and 687 million yuan, respectively [6] - The in vitro diagnostic business revenue during this period surged, reaching 499 million yuan in 2022, accounting for 72.71% of total revenue [6] Future Outlook - The company plans to completely phase out its in vitro diagnostic products by 2025, focusing solely on food safety and animal diagnostics [7][8] - Despite a strategic pivot, the company has faced challenges, with non-recurring net profits remaining negative for two and a half years [8][9]

Core Viewpoint - The announcement from Yirui Biotechnology (300942.SZ) reveals plans for share reduction by its controlling shareholder and associated parties, indicating a potential liquidity event without significant impact on the company's governance or control structure [1][2]. Share Reduction Plan - Yirui (Hainan) Venture Capital Co., Ltd. plans to reduce its holdings by up to 11,521,758 shares, representing 2.84% of the total share capital, while associated entities plan to reduce their holdings by 288,500 shares (0.07%) and 341,800 shares (0.08%) respectively, totaling a maximum reduction of 12,152,058 shares or 3% of the total [1][2]. - The estimated cash proceeds from the planned share reduction amount to approximately 127.6 million yuan based on the last closing price of 10.50 yuan per share [1]. Current Shareholding Structure - As of the announcement date, Yirui Venture Capital holds 132,369,971 shares (32.68%), Yida Rui holds 19,008,003 shares (4.69%), and Yikai Rui holds 22,577,203 shares (5.57%) [2]. Previous Share Reduction Activities - Recent share reductions included Yirui Venture Capital selling 3,531,208 shares at an average price of 10.66 yuan per share, and the actual controller Zhu Hai reducing his holdings through various transactions, totaling approximately 125 million yuan from July to September 2025 [3]. Fundraising and Financial Performance - Yirui Biotechnology raised a total of 5.45 billion yuan from two fundraising events, with net profits for the years 2021 to 2024 showing fluctuations, including a loss of approximately 184.9 million yuan in 2023 [4][6].

易瑞生物(300942.SZ)今日早盘一度跌7.81%至9.68元，股价创今年7月15日以来近3个月新低。易瑞生物公告称，公司控股股东易瑞创投及其一致行动人易达 瑞、易凯瑞计划自公告披露之日起15个交易日后的3个月内，以集中竞价或大宗交易方式减持公司股份，合计不超过公司总股本的3%。(格隆汇) ...

Core Viewpoint - The major shareholders of Easyway Bio (300942) plan to reduce their holdings in the company by up to 3% of the total share capital within three months, starting from the announcement date, due to personal funding needs [1][2]. Shareholder Reduction Plans - The controlling shareholder, Easyway (Hainan) Venture Capital Co., Ltd., intends to reduce its holdings by up to 11,521,758 shares, representing 2.84% of the total share capital [1]. - Easyway's other shareholders, Easy Dary and Easy Kairui, plan to reduce their holdings by up to 288,500 shares (0.07%) and 341,800 shares (0.08%), respectively [1]. - The total reduction across all shareholders will not exceed 3% of the company's total share capital [2]. Previous Share Reduction - Last month, the controlling shareholder completed a reduction of 4,167,000 shares, accounting for 1.03% of the total share capital, between September 2 and September 5, 2025 [2]. - Following the previous reduction, the total shares held by the controlling shareholder decreased from 23,829,340 shares to 23,412,640 shares, reducing their ownership percentage from 58.83% to 57.80% [2]. Company Financial Performance - In the first half of 2025, the company reported revenue of 109 million yuan, a year-on-year increase of 5.4% [3]. - The net profit attributable to shareholders was 2.34 million yuan, a recovery from a loss of 1.56 million yuan in the same period last year [3]. - The company's stock price decreased by 3.40% to 10.50 yuan per share as of October 10, with a market capitalization of 4.253 billion yuan, although the stock has risen by 22.75% year-to-date [3].

Performance Disclosure - Hengdian East Magnetic expects a net profit attributable to shareholders of 1.39 billion to 1.53 billion yuan for the first three quarters, representing a year-on-year increase of 50.1% to 65.2% [1] - China Nuclear Power reported a cumulative commercial power generation of 184.364 billion kWh for the first three quarters, a year-on-year increase of 14.95% [2] - Yangtze Power's total power generation from its domestic cascade power stations was approximately 235.126 billion kWh for the first three quarters, remaining roughly flat compared to the previous year [2] Shareholding Changes - Zhongrong Electric's employee shareholding platform plans to reduce its stake by no more than 1% of the company's total shares [3] - Eryi Biological's controlling shareholder and its concerted parties plan to reduce their stake by no more than 3% of the company's total shares [4] - Lian Ce Technology's actual controller's concerted parties plan to reduce their stake by no more than 2.98% of the company's total shares [5] Risk Matters - Wentai Technology announced that the Dutch government has frozen the assets of its subsidiary, Anshi Semiconductor, for one year, affecting its revenue of approximately 14.7 billion yuan in 2024 [6] Share Transfer - Zhongzhi Holdings announced that its major shareholder, Changjiang Ecological Environmental Group, intends to transfer all of its 63.133 million shares, accounting for 24.73% of the total shares, at a price not lower than 8.72 yuan per share [7] Company Clarification - Haiou Zhugong clarified that it has not participated in any form of lighthouse factory qualification application or recognition, despite media reports linking it to the "lighthouse factory concept" [8]

Core Insights - On October 12, no A-share listed companies disclosed any increase in shareholding, while six companies reported share reductions [1] Group 1: Companies Reporting Share Reductions - Lian Ce Technology's controlling shareholder's concerted actors plan to reduce their holdings by no more than 2.98% [2] - Baolidi's shareholder holding over 5% (Yunnan Trust) plans to reduce holdings by no more than 1 million shares [2] - Zhongrong Electric's controlling shareholder's concerted actors intend to reduce their holdings by no more than 0.999% [2] - Ketaobiological's specific shareholder Zhang Liebing plans to reduce holdings by no more than 1.8976% [2] - Yirui Biological's controlling shareholder and its concerted actors plan to reduce holdings by no more than 3% [2] - Shanghai Hohong's major shareholder Xinggang Rongchuang plans to reduce holdings by no more than 1% [2]

Core Viewpoint - The company, EasyRegen Biotech (300942), announced plans for its major shareholders to reduce their stake in the company by up to 12.15 million shares, representing 3% of the total share capital [1] Group 1 - The controlling shareholder, EasyRegen Investment, along with its concerted parties, EasyDaRui and EasyKaiRui, intends to execute the share reduction through centralized bidding or block trading [1]

北京商报讯（记者 丁宁）10月12日晚间，易瑞生物（300942）发布公告称，公司的控股股东易瑞（海 南）创业投资有限公司及其一致行动人深圳易达瑞管理咨询合伙企业（有限合伙）和深圳易凯瑞管理咨 询合伙企业（有限合伙）计划自公告披露之日起15个交易日后的3个月内以集中竞价或大宗交易方式减 持公司股份，减持比例合计不超过公司总股本的3%。 ...

易瑞生物公告称，公司控股股东易瑞创投及其一致行动人易达瑞、易凯瑞计划自公告披露之日起15个交 易日后的3个月内，以集中竞价或大宗交易方式减持公司股份，合计不超过公司总股本的3%。其中，易 瑞创投拟减持不超过11,521,758股（占公司总股本2.84%），易达瑞拟减持不超过288,500股（占公司总 股本0.07%），易凯瑞拟减持不超过341,800股（占公司总股本0.08%）。减持价格将根据市场价格确 定，且不低于公司首次公开发行股票的发行价格。 ...